Revised Press Release enclosed

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹780.00

prior close

₹801.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2+1.0+0.8+0.4-1.3-0.5-2.2-1.3-3.0-3.8+0.0-1.7+1.2—

Up moveDown movePending

AI summary

Anthem Biosciences reported strong FY26 results with consolidated revenue of ₹21,243 Mn (up 15.2% YoY) and PAT of ₹5,918 Mn (up 31.1% YoY). Q4FY26 was particularly strong with revenue of ₹6,109 Mn (up 26.4% YoY) and PAT of ₹1,898 Mn (up 129.8% YoY). EBITDA margins expanded to 43.4% for FY26 and 48.1% for Q4FY26. The company recorded an exceptional item of ₹244 Mn due to new labour code provisions. CRDMO business grew 17.7% YoY to ₹17,727 Mn. The company maintains a healthy net cash position of ₹13,743 Mn.

Likely market impact

Strong operational performance with margin expansion signals operational efficiency improvements. The 26%+ quarterly revenue growth and 129% PAT growth in Q4 demonstrate accelerating momentum, which is positive for shareholders. The exceptional labour code item is a non-recurring charge.